---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-002580"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2022-04-13T23:59:59+00:00"
generated_at: "2026-06-26T07:35:47.454827+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte raises CEO and CFO salaries; Nasdaq confirms listing compliance

## Summary
- CEO Kenneth Waggoner salary increased from $375K to $520K, retroactive to Jan 1, 2022.
- CFO Carlos Trujillo salary increased from $275K to $380K, retroactive to Jan 1, 2022.
- Nasdaq Staff determined company meets independent director requirement after appointing Dr. Matthias Löhr.

## SEC filing metadata
- accession: 0001683168-22-002580
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2022-04-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316822002580/0001683168-22-002580-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316822002580/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-002580
- JSON: https://secwatch.observer/filing/0001683168-22-002580.json
- Plain text: https://secwatch.observer/filing/0001683168-22-002580.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.